-The Indian Express As the 2015 target for achieving millennium development goals adopted in 1990 approaches, the time has come to take stock of various countries’ performances and identify areas that need more attention. The Unicef recently released a report which categorically stated that India will not be able to achieve the goal of an under-five mortality rate (U5MR) of 42 by 2015. The report further stated that only six of...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...

-The Telegraph A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy. The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV. India’s...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...